Get the latest news, updates, funding opportunities and essential information for members of the Brigham research community 
Course Overview
Solid organ transplant recipients are at 3-10 times higher risk of cancer compared to non-transplant patients, due to long-standing immunosuppression. Cellular therapies, such as CAR-T or virus-specific T cell therapies, have emerged as novel therapies for cancers and infectious diseases, but their use in transplant patients is challenging because of safety and efficacy concerns.
As there has been a growing data on cellular therapies in transplant population, the goals of our conference are to learn up-to-date cellular therapies treatment options for transplant patients, and to learn patients’ perspectives from those living with cancer post-transplants.
Learning Objectives
- Understand the cancer burden in transplant recipients
- Learn up-to-date cellular therapies for transplant patients
- Learn patients’ perspectives from those living with cancer post-transplant
Target Audience
This course is targeted to transplant clinicians (nephrologists, surgeons, advanced practitioners, nurses, social workers), oncologists, as well as transplant recipients and their care partners.
Course Faculty
Course Director
Assistant Professor, Harvard Medical School
Associate Physician, Transplant Nephrology, Brigham and Women’s Hospital
Course co-directors
Ala Abudeyyeh – MD Anderson Cancer Center
Christopher Blosser – University Washington, Fred Hutch Cancer Institute
Edgar Jaimes – Memorial Sloan Kettering Cancer Center (MSKCC)
Agenda
9:00-9:05 Opening Remarks
9:05-10:10 CAR-T Therapies for Kidney Transplant Recipients
Nephrology, University of Washington, Seattle
“CAR-T therapy for kidney transplant recipients- nephrologist’s view”
Transfusion Medicine, University of Pennsylvania
“CAR-T therapies for kidney transplant recipients- immunologists’ view”
Hematology, Memorial Sloan Kettering Cancer Center
“Virus Specific & Chimeric Antigen Receptor T-cells for PTLD after Solid Organ Transplants”
10:10-10:35 Virus-specific T Cell Therapies
Oncology, MD Anderson Cancer Center
“Engineered virus-specific T cell therapies for solid organ transplant recipients”
10:35-11:25 Treg, CAR-Treg Therapies in Transplant Tolerance and Desensitization
Department of Medicine/ Nephrology, Stanford
“Overview of cellular therapies for transplant tolerance”
Transplantation Research Immunology Group, University of Oxford
“Autologous Treg therapies for solid organ transplantation”
11:25-11:55 Patients’ Perspectives (Patient Roundtable)
11:55-12:00 Closing Remarks
Support
